Keytruda (pembrolizumab, Merck & Co) was just FDA-approved to treat patients with advanced (metastatic) NSCLC with tumors that express a protein called PD-L1, according to an agency news release.
GlaxoSmithKline and Theravance have announced their intent to file a new drug application in Japan for Relvar Ellipta, a combination inhaler for COPD.
PRAXIS is an interactive online community designed to support COPD caregivers and administrators to prevent and reduce hospital admissions and readmissions by improving care across the COPD care continuum.
For the first time, European researchers have succeeded in defining three distinct types of severe asthma by analyzing patient sputum samples, according to research presented at ERS 2015.
A pooled analysis from three phase III studies show a 38% reduction in risk of death after up to two years on Esbriet treatment.
With the Improving Access to Clinical Trials Act (IACT) of 2009 set to expire on October 5, 2015, the Cystic Fibrosis Foundation championed a new bill to make the IACT legislation permanent.
Tri-anim Health Services and parent company Sarnova have entered into a master distribution agreement with Ambu to distribute Ambu's videoscope, laryngoscope, laryngeal masks, and pain management products.
A US doctor used materials aboard his Transatlantic aircraft to create a nebulizer and delivered oxygen and medication to an asthmatic toddler in distress.
Occupational exposure to fluid commonly used in metal machining operations may be related to a rare, irreversible lung disease called lymphocytic bronchiolitis, according to research presented at ERS 2015.
University of Southern Indiana will transition its two-year Associate's degree to a four-year Bachelor of Science in Respiratory Therapy (BSRT) degree in fall 2016.
Personalized medicine for conditions such as asthma and COPD will be a key theme at the European Respiratory Society International Congress 2015.
A new report on the blood gas and electrolyte analyzer market estimates the market to grow at a CAGR of 6.1% during 2014 to 2019.
LTRAs cut the risk for an exacerbation by 40% compared with placebo, and -- as add-on therapy to ICS -- reduced exacerbation risks by 20%.
Boehringer Ingelheim will present new data at ERS 2015 on Spiolto Respimat for COPD, OFEV for IPF, and Spiriva Respimat in asthma.
Under the 2010 health law, Medicare payments to hospitals can be affected by patient satisfaction surveys.
Promedior has announced the beginning of the second phase of their PRM-151 clinical trial in patients with idiopathic pulmonary fibrosis.
Proteostasis Therapeutics has raised $37 million in new funding to develop its lead product candidate for the treatment of cystic fibrosis.
The FDA has granted a Fast Track designation to MediciNova's drug formulation MN-001 aimed at treating idiopathic pulmonary fibrosis (IPF).
A new report published by Transparency Market Research estimates that the global asthma and COPD market is expected to reach $26.9 billion in 2017.
Taking rebates and discounts into account, pricing for branded meds in the US grew by less than 1% last quarter, compared with 4.4% during the same period last year.